Dedicated to Kidney and Electrolyte Health Nephcentric is the developer of guideline supported, evidence based therapeutics for people with: Hyponatremia/SIADH/SIAD (low sodium) Hypomagnesemia – Especially those intolerant to or uncontrolled on traditional magnesium therapy Kidney Stones We specialize in solving unmet clinical needs by developing specialized medical foods, which require clinical evidence and scientific backing.
Natera
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment response monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. Signatera is personalized and tumor-informed, providing each individual with a customized blood test, tailored to fit the unique signature of clonal mutations found in that individual’s tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions. Learn more at: natera.com/oncology | We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that lead to longer, healthier lives. | ASN Natera provides advanced DNA technology that enables the nephrology community to deliver quality, personalized care. Natera offers solutions that are efficient, reliable, and accessible to patients and practices. Renasight is a comprehensive gene panel that analyzes over 390 genes associated with kidney disease to provide you and your patients insights for personalized care. Learn more at www.natera.com/organ-health/renasight-genetic-testing/
Natera
Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment response monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. Signatera is personalized and tumor-informed, providing each individual with a customized blood test, tailored to fit the unique signature of clonal mutations found in that individual’s tumor. Signatera is intended to detect and quantify cancer left in the body, at levels down to a single tumor molecule in a tube of blood, to identify recurrence earlier and to help optimize treatment decisions. Learn more at: natera.com/oncology | We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that lead to longer, healthier lives. | ASN Natera provides advanced DNA technology that enables the nephrology community to deliver quality, personalized care. Natera offers solutions that are efficient, reliable, and accessible to patients and practices. Renasight is a comprehensive gene panel that analyzes over 390 genes associated with kidney disease to provide you and your patients insights for personalized care. Learn more at www.natera.com/organ-health/renasight-genetic-testing/
MediBeacon Inc.
www.medibeacon.com
Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney disease. The company is advancing a pipeline designed to translate insights from protective genetic variants into potential new therapies, led by investigational programs in APOL1-mediated kidney disease and chronic kidney disease.
Kibow Biotech
Kibow® Biotech is a biotechnology company founded in 1997 and is based in suburban Philadelphia. Kibow specializes in the development and commercialization of live bio-therapeutics to slow the progression of Chronic Kidney Disease and related conditions.
ImmunoWork
ImmunoWork is a Medtech startup developing innovative diagnostic tests and targeted therapies for autoimmune glomerular diseases to help nephrologists create personalized treatment plans and preserve kidney function.
GSK
Oncology is an emerging therapeutic area for GSK where we are committed to maximising patient survival with a current focus on haematologic malignancies, gynaecologic cancers, and other solid tumours through breakthroughs in immuno-oncology and tumour-cell targeting therapies. | GSK unites science, technology and talent to get ahead of disease together. We prevent and treat disease with vaccines, specialty and general medicines | GSK is a world-leading research-based healthcare company committed to advancing innovation through robust R&D. By harnessing the science of the immune system, human genetics, and advanced technologies, we develop new and specialty products. Our science-led vaccines business spans discovery through late-phase development, continuously working to accelerate vaccine development and strengthen supply performance. Strategic partnerships are vital for achieving a greater positive impact for patients worldwide. | We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. We prioritize innovation in vaccines, specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system and advanced technologies, and our world-leading capabilities in vaccines and medicines development. For further information, please visit www.gsk.com
Emerald Clinical Trials
Emerald Clinical Trials is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 500 people managing 39 geographical locations throughout the Asia-Pacific region, USA, and Europe, Emerald Clinical Trials provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration and post-marketing trials.
Eleva
Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough technology platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential. https://elevabiologics.com | Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biological therapeutics. Eleva’s disruptive moss-based technology platform enables GMP-scale manufacturing of human proteins with tremendous therapeutic potential that have been too challenging to manufacture using other approaches. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. The lead program, CPV-104 recombinant human complement Factor H, is in Phase 1b testing to treat C3 Glomerulopathy (C3G). An intravitreal formulation of the candidate is in late preclinical development to treat dry AMD. The company’s aGal (RPV-001) program has completed a positive Phase 1b single-dose clinical trial to treat Fabry disease.